Background Obesity and depression are common comorbid conditions. The objective of the
study was to evaluate the effect of obesity on the pharmacokinetics of the serotonergic …

Vortioxetine is a novel antidepressant with multimodal activity currently approved for the
treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5-to …

Three phase 1 randomized single‐center studies assessed the pharmacokinetics, safety,
and tolerability of vortioxetine after single‐and multiple‐dose administration in healthy …

Introduction Because the multimodal antidepressant vortioxetine is likely to be
coadministered with other central nervous system (CNS)-active drugs, potential drug–drug …

Vortioxetine is approved for the treatment of major depressive disorder (MDD). This analysis
aimed to develop pharmacokinetic (PK) and PK/Efficacy models to evaluate the exposure …

ABSTRACT Context: Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of
action thought to be related to a combination of 2 pharmacologic actions: direct modulation …

Introduction Major depressive disorder (MDD) is associated with a significant burden of
disease in China. Awareness and better access to treatments could help alleviate the …

Background: This 8-week, randomized, double-blind, placebo-controlled study, conducted
August 2010–May 2012 in the United States, evaluated the safety and efficacy of …

Objective: This article summarizes the US Food and Drug Administration's (FDA's) review of
the New Drug Application for vortioxetine, especially the clinical efficacy and safety data. It …

Introduction: Major depressive disorder (MDD), one of the most common disorders in
medical practice and one of the leading causes of disability worldwide, is frequently …